Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: Relative area under the curve effectiveness and sequence effects

Journal of Rheumatology

Volumn 29, Issue 8, 2002, Pages 1639-1645

  Hurst, Stacey ^a   Kallan, Michael J ^a   Wolfe, Frederick J ^a   Fries, James F ^a   Albert, Daniel A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dmard area under the curve; Observational; Rheumatoid arthritis; Therapy

Indexed keywords

GOLD SALT; HYDROXYCHLOROQUINE; METHOTREXATE; ANTIRHEUMATIC AGENT; ORGANOGOLD COMPOUND;

ADULT; AREA UNDER THE CURVE; ARTICLE; DISABILITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT OUTCOME; DRUG ADMINISTRATION; HEALTH STATUS; INTRAMUSCULAR DRUG ADMINISTRATION; PATHOPHYSIOLOGY; QUESTIONNAIRE;

ANTIRHEUMATIC AGENTS; ANTIRHEUMATIC AGENTS, GOLD; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; HEALTH STATUS; HUMAN; HYDROXYCHLOROQUINE; INJECTIONS, INTRAMUSCULAR; METHOTREXATE; QUESTIONNAIRES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TREATMENT OUTCOME; HUMANS; ORGANOGOLD COMPOUNDS;

EID: 0036021136     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses
2. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial
3. Efficacy of low-dose methotrexate in rheumatoid arthritis
4. Gold therapy in rheumatoid arthritis. Report of a multi-centre controlled trial
5. Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial
6. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis
7. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
8. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
9. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
10. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
11. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
12. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
13. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis
14. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study
15. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial
16. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial
17. The Prosorba column for treatment of refractory rheumatoid arthritis: A randomized, double-blind, sham-controlled trial
18. Azathioprine versus D-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold
19. A controlled trial of cyclophosphamide in rheumatoid arthritis
20. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis
21. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients
22. Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials
23. Reevaluating the therapeutic approach to rheumatoid arthritis: The "sawtooth" strategy
24. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease
25. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis
26. Innovative treatment approaches for rheumatoid arthritis. Combination therapy
27. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
28. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
29. Modeling therapeutic strategies in rheumatoid arthritis: Use of decision analysis and Markov models
30. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts
31. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
32. Radiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression
33. Listening to the patient: A practical guide to self-report questionnaires in clinical care
34. Health status questionnaires
35. Measurement of patient outcome in arthritis
36. The assessment and prediction of functional disability in rheumatoid arthritis
37. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies
38. A survey of United States rheumatologists concerning effectiveness of disease-modifying antirheumatic drugs and prednisone in the treatment of rheumatoid arthritis
39. The prognosis of rheumatoid arthritis: Assessment of disease activity and disease severity in the clinic
40. Critical issues in longitudinal and observational studies: Purpose, short versus long term, selection of study instruments, methods, outcomes, and biases
41. A reappraisal of HAQ disability in rheumatoid arthritis
42. Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy
43. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the disease
44. Remission in rheumatoid arthritis
45. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials
46. Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration
47. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study
48. The effectiveness of early treatment with "second-line" antirheumatic drugs: A randomized controlled trial
49. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategy